Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta …
H Liu, Y Wu, T Lv, Y Yao, Y Xiao, D Yuan, Y Song - PLoS one, 2013 - journals.plos.org
Background The aim of this study was to assess the role of skin rash in predicting the
efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and the …
efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and the …
Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis …
F Petrelli, K Borgonovo, M Cabiddu, V Lonati, S Barni - Lung cancer, 2012 - Elsevier
BACKGROUND: Dermatological toxicity, usually in the form of acneiform rash, is frequently
observed in non-small-cell lung cancer (NSCLC) patients treated with anti-EGF receptor …
observed in non-small-cell lung cancer (NSCLC) patients treated with anti-EGF receptor …
A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
JJ Yang, Q Zhou, HH Yan, XC Zhang, HJ Chen… - British journal of …, 2017 - nature.com
Background: A phase III trial was conducted to compare the safety and efficacy of erlotinib
with that of gefitinib in advanced non-small cell lung cancer harbouring epidermal growth …
with that of gefitinib in advanced non-small cell lung cancer harbouring epidermal growth …
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
PURPOSE: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis
BC Garden, S Wu, ME Lacouture - Journal of the American Academy of …, 2012 - Elsevier
BACKGROUND: The overall incidence and risk of nail changes associated with the use of
epidermal growth factor receptor inhibitors (EGFRIs) varies widely across the literature …
epidermal growth factor receptor inhibitors (EGFRIs) varies widely across the literature …
Serum lactate dehydrogenase levels at presentation in stage IV non-small cell lung cancer: predictive value of metastases and relation to survival outcomes
DS Lee, KR Park, SJ Kim, MJ Chung, YH Lee… - Tumor Biology, 2016 - Springer
This study aimed to evaluate the clinical correlations between serum lactate dehydrogenase
(LDH) levels and tumor characteristics and to investigate the prognostic impact of serum …
(LDH) levels and tumor characteristics and to investigate the prognostic impact of serum …
An audit of immunohistochemical marker patterns in meningioma
DS Baxter, A Orrego, JV Rosenfeld… - Journal of Clinical …, 2014 - Elsevier
Meningiomas may express a number of potentially growth-promoting receptors including
receptors for progesterone, growth hormone and vascular endothelial growth factor (VEGF) …
receptors for progesterone, growth hormone and vascular endothelial growth factor (VEGF) …
Acquired mitochondrial abnormalities, including epigenetic inhibition of superoxide dismutase 2, in pulmonary hypertension and cancer: therapeutic implications
SL Archer - Hypoxia: Translation in Progress, 2016 - Springer
There is no cure for non-small-cell lung cancer (NSCLC) or pulmonary arterial hypertension
(PAH). Therapies lack efficacy and/or are toxic, reflecting a failure to target disease …
(PAH). Therapies lack efficacy and/or are toxic, reflecting a failure to target disease …
Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non …
WX Qi, Z Shen, F Lin, YJ Sun, DL Min… - Asian Pacific journal …, 2012 - koreascience.kr
Purpose: To compare the efficacy and safety of epidermal growth factor receptor tyrosine
kinase inhibitormonotherapy (EFGR-TKIs: gefitinib or erlotinib) with standard second-line …
kinase inhibitormonotherapy (EFGR-TKIs: gefitinib or erlotinib) with standard second-line …
Review of chemotherapy‐associated paronychia
MK Gupta, SR Lipner - International journal of dermatology, 2022 - Wiley Online Library
Chemotherapy‐associated paronychia (CAP) is an inflammation of the nail folds in response
to various chemotherapeutic medications. Altered proliferation of keratinocytes or nail matrix …
to various chemotherapeutic medications. Altered proliferation of keratinocytes or nail matrix …